Back to results
US 10,239,893 B2Granted
Controlling the isomerization rate of Azo-BF2 switches using aggregation
AssigneeTrustees of Dartmouth College
InventorsIvan Abrahamian, Russell P. Hughes, Yin Nelson, Hai Qian
Life of this patent
Estimating the term…
Abstract
Provided herein are photochromic organic compounds of Formula I or Formula II, which are useful as molecular switches capable of being triggered via a cis/trans isomerization process. Methods of using the molecular switch compounds to form photopharmaceutical compounds that may be used to provide selective spatiotemporal activation of pharmaceutical agents are also disclosed.
Claims6
A method of controlling the isomerization rate of a compound, comprising:
- (a) selecting a compound capable of isomerizing between a thermally stable isomer and a kinetic isomer, and wherein thermal relaxation is concentration-dependent;
- (b) providing a solution of the compound having a preset concentration of the compound;
- (c) exposing the solution to electromagnetic radiation having a wavelength effective to cause isomerization of the compound in the solution to the kinetic isomer;
- and
- (d) shielding the solution from electromagnetic radiation to allow for thermal relaxation of the kinetic isomer, thereby controlling the isomerization rate of the compound, wherein the preset concentration is determined by:
- (e) measuring the number of molecules of the compound per unit volume (concentration) that provides a desired half-life of the kinetic isomer, step (e) preceding step (b);
- wherein the compound is of Formula II:
- or a salt thereof, wherein
- N═N—R2 can be oriented cis or trans to the tricycle;
- R1 is H, CN, CO2H, CO2(C1-6-alkyl), C1-6-alkyl, C6-19-aryl, OH, O(C1-6-alkyl), OC(O)(C1-6-alkyl), NH2, NH(C1-6-alkyl), N(C1-6-alkyl)2, or NHC(O)(C1-6-alkyl);
- R2 is phenyl;
- and
- R3, R4, R5, R6, Wand R8 are each, independently, H, C1-6-alkyl, C6-19-aryl, OH, O(C1-6-alkyl), OC(O)(C1-6-alkyl), NH2, NH(C1-6-alkyl), N(C1-6-alkyl)2, NHC(O)(C1-6-alkyl) or a group corresponding to a small molecule pharmaceutical;
- or
- R3 and R4, R4 and R5, R5 and R6 or R7 and R8 can, when taken together, form a fused aryl, fused heteroaryl, fused C3-6-cycloalkyl, or fused heterocycle, wherein the fused aryl, fused heteroaryl, fused cycloalkyl, or fused heterocycle can be optionally substituted one or more times with C1-6-alkyl, C6-19-aryl, OH, O(C1-6-alkyl), OC(O)(C1-6-alkyl), NH2, NH(C1-6-alkyl), N(C1-6-alkyl)2, or NHC(O)(C1-6-alkyl), wherein said step (c) takes place in a mammalian cell.
12 more elements
A method of controlling the isomerization rate of the compound:
- comprising:
- (a) providing a solution of the compound having a preset concentration of the compound;
- (b) exposing the solution to electromagnetic radiation having a wavelength effective to cause isomerization of the compound in the solution to the kinetic isomer;
- and
- (c) shielding the solution from electromagnetic radiation to allow for thermal relaxation of the kinetic isomer, thereby controlling the isomerization rate of the compound, wherein selecting the preset concentration of the compound comprises:
- (i) extrapolating from a graph of concentration versus half-life or isomerization rate;
- (ii) utilizing a look-up table of concentration versus half-life or isomerization rate for the compound;
- or
- (iii) measuring the number of molecules of the compound per unit volume (concentration) that provides a desired half-life of the kinetic isomer.
6 more elements
Dependencies are inferred from the claim text.